Patients with Cowden syndrome carry a significantly elevated risk of thyroid malignancy. When thyroid cancer develops in this setting, it characteristically presents as follicular or papillary carcinoma, requiring a structured multi-modality approach adapted to the extent of disease.
Thyroid cancers arising in the context of Cowden syndrome are specifically follicular or papillary carcinomas. The co-occurrence of this hereditary syndrome with thyroid malignancy shapes the selection and sequencing of treatment.
Management involves surgical intervention as a central component, with the specific operative extent determined by the degree of disease progression. Surgical treatment is combined with additional systemic and isotope-based therapies.
As described above, thyroid cancers that occur in patients with this syndrome are follicular or papillary carcinomas.
Therefore, surgical treatment, anticancer drug therapy, and intravenous radioiodine therapy are performed as the standard treatments for follicular or papillary carcinoma.
Surgical treatment includes adenomectomy, subtotal thyroidectomy, or total thyroidectomy depending on the degree of progression and lymph node dissection.
View source ↗